Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27

被引:43
|
作者
Montgomery, HE
Kiernan, LA
Whitworth, CE
Fleming, S
Unger, T
Gohlke, P
Mullins, JJ
McEwan, JR
机构
[1] UCL, Sch Med, Hatter Inst Cardiovasc Studies, London W1N 8AA, England
[2] Univ Edinburgh, Ctr Genome Res, Edinburgh, Midlothian, Scotland
[3] Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland
[4] Univ Kiel, Inst Pharmacol, Kiel, Germany
关键词
renin-angiotensin system; malignant hypertension; transgenic rats;
D O I
10.1097/00004872-199816050-00011
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Activation of the renin-angiotensin system has been implicated strongly in the transition from benign to malignant hypertension. However, the concomitant rise in blood pressure might also have a direct effect on the vascular wall by initiating fibrinoid necrosis and myointimal proliferation, Ascertaining the relative importance of these two factors in this process has proved difficult. TGR(mREN2)27 heterozygotes (HanRen2/Edin--) have previously been shown to develop malignant hypertension spontaneously and exhibit the characteristic features of human malignant hypertension, Objective Tissue renin-angtiotensin systems have been implicated in the pathogenesis of malignant hypertension, We set out to determine whether inhibition of this system might protect against development of the disease in a rat model, Method Male TGR(mREN2)27 heterozygotes (n = 24) were given a non-hypotensive dose of the angiotensin converting enzyme inhibitor ramipril (5 mu g/kg per day) from 28 to 120 days of age, untreated rats acting as controls (n = 40), The incidences of malignant hypertension were compared. Systolic blood pressure was measured by tail-cuff plethysmography during treatment; tissue and plasma angiotensin converting enzyme levels and renal histological changes were assessed at the end of the treatment period or upon development of malignant hypertension. Results Sixty-three per cent of control rats and 4% of angiotensin converting enzyme inhibitor-treated rats had developed malignant hypertension by 120 days despite there having been no significant difference in systolic blood pressure throughout the course of treatment. Angiotensin converting enzyme activities in kidney, heart and resistance vessels, though not that in plasma, were significantly lower in the treated rats, The degree of medial wall thickening did not differ between the two groups whereas evidence of tissue injury (e.g. intimal fibrosis, fibrinoid necrosis and nephron injury) was significantly less common among rats in the angiotensin converting enzyme inhibitor-treated group, Conclusions Tissue angiotensin converting enzyme inhibition at a non-hypotensive dose almost completely prevented mortality from malignant hypertension and significantly reduced tissue injury in this model, implicating angiotensin II rather than high blood pressure as the principal 'vasculotoxic' agent in malignant hypertension, (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:635 / 643
页数:9
相关论文
共 50 条
  • [41] ANGIOTENSIN-II RECEPTOR BLOCKADE IN TCR(MREN2)27 - EFFECTS OF RENIN-ANGIOTENSIN-SYSTEM GENE-EXPRESSION AND CARDIOVASCULAR FUNCTIONS
    BOHM, M
    LEE, MA
    KREUTZ, R
    KIM, S
    SCHINKE, M
    DJAVIDANI, B
    WAGNER, J
    KALING, M
    WIENEN, W
    BADER, M
    GANTEN, D
    JOURNAL OF HYPERTENSION, 1995, 13 (08) : 891 - 899
  • [42] Differentiated response of the sympathetic nervous system to angiotensin-converting enzyme inhibition in hypertension
    Johansson, M
    Elam, M
    Rundqvist, B
    Eisenhofer, G
    Herlitz, H
    Jensen, G
    Friberg, P
    HYPERTENSION, 2000, 36 (04) : 543 - 548
  • [43] Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation - Evidence for tissue angiotensin-converting enzyme function
    Morishita, R
    Gibbons, GH
    Tomita, N
    Zhang, LN
    Kaneda, Y
    Ogihara, T
    Dzau, VJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (04) : 915 - 922
  • [44] Central Angiotensin-(1-7) Improves Vagal Function Independent of Blood Pressure in Hypertensive (mRen2)27 Rats
    Nautiyal, Manisha
    Shaltout, Hossam A.
    de Lima, Daniel C.
    do Nascimento, Kenia
    Chappell, Mark C.
    Diz, Debra I.
    HYPERTENSION, 2012, 60 (05) : 1257 - 1265
  • [45] SENSITIVE METHOD FOR QUANTITATION OF ANGIOTENSIN-CONVERTING ENZYME (ACE) ACTIVITY IN TISSUE
    MENG, QC
    BALCELLS, E
    DELLITALIA, L
    DURAND, J
    OPARIL, S
    BIOCHEMICAL PHARMACOLOGY, 1995, 50 (09) : 1445 - 1450
  • [46] ALTERATIONS OF CARDIAC ALPHA-ADRENOCEPTORS AND BETA-ADRENOCEPTORS AND INOTROPIC RESPONSIVENESS IN HYPERTENSIVE TRANSGENIC RATS HARBORING THE MOUSE RENIN GENE (TGR(MREN2)27)
    TAWFIKSCHLIEPER, H
    MOLL, M
    SCHMID, B
    SCHWINGER, RHG
    PAUL, M
    GANTEN, D
    BOHM, M
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 1995, 17 (04) : 631 - 648
  • [47] NEUTRAL ENDOPEPTIDASE VERSUS ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN ESSENTIAL-HYPERTENSION
    FAVRAT, B
    BURNIER, M
    NUSSBERGER, J
    LECOMTE, JM
    BROUARD, R
    WAEBER, B
    BRUNNER, HR
    JOURNAL OF HYPERTENSION, 1995, 13 (07) : 797 - 804
  • [48] Imbalance Between Pulmonary Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Activity in Acute Respiratory Distress Syndrome
    Wosten-van Asperen, Roelie M.
    Bos, Albert P.
    Bem, Reinout A.
    Dierdorp, Barbara S.
    Dekker, Tamara
    van Goor, Harry
    Kamilic, Jelena
    van der Loos, Chris M.
    van den Berg, Elske
    Bruijn, Martijn
    van Woensel, Job B.
    Lutter, Rene
    PEDIATRIC CRITICAL CARE MEDICINE, 2013, 14 (09) : E438 - E441
  • [49] HYPERTENSION IN THE TRANSGENIC RAT TGR(MREN-2)27 MAY BE DUE TO ENHANCED KINETICS OF THE REACTION BETWEEN MOUSE RENIN AND RAT ANGIOTENSINOGEN
    TOKITA, Y
    FRANCOSAENZ, R
    REIMANN, EM
    MULROW, PJ
    HYPERTENSION, 1994, 23 (04) : 422 - 427
  • [50] Activity of angiotensin-converting enzyme after treatment with L-arginine in renovascular hypertension
    Gouvea, SA
    Bissoli, NS
    Moysés, MR
    Cicilini, MA
    Pires, JGP
    Abreu, GR
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2004, 26 (06) : 569 - 579